Fidelity Investments’s Ventyx Biosciences VTYX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-11,422
Closed -$103K 5575
2025
Q4
$103K Sell
11,422
-1,580
-12% -$11.8K ﹤0.01% 3743
2025
Q3
$40.4K Sell
13,002
-444
-3% -$1.18K ﹤0.01% 4073
2025
Q2
$28.8K Sell
13,446
-29,620
-69% -$47.8K ﹤0.01% 4140
2025
Q1
$49.5K Buy
43,066
+5,943
+16% +$10.2K ﹤0.01% 3865
2024
Q4
$81.3K Sell
37,123
-93,763
-72% -$212K ﹤0.01% 3641
2024
Q3
$285K Buy
130,886
+3,854
+3% +$8.86K ﹤0.01% 3075
2024
Q2
$293K Sell
127,032
-251,589
-66% -$1.05M ﹤0.01% 2909
2024
Q1
$2.08M Buy
378,621
+309,138
+445% +$1.41M ﹤0.01% 2326
2023
Q4
$172K Sell
69,483
-8,608,046
-99% -$81.8M ﹤0.01% 3011
2023
Q3
$301M Buy
8,677,529
+124,298
+1% +$4.3M 0.03% 553
2023
Q2
$281M Buy
8,553,231
+948,890
+12% +$32.7M 0.02% 597
2023
Q1
$255M Buy
7,604,341
+5,909,854
+349% +$230M 0.02% 617
2022
Q4
$55.6M Sell
1,694,487
-201,325
-11% -$5.96M 0.01% 1215
2022
Q3
$65.4M Buy
1,895,812
+319,870
+20% +$7.08M 0.01% 1134
2022
Q2
$19.3M Buy
1,575,942
+758,903
+93% +$11.3M ﹤0.01% 1663
2022
Q1
$11.1M Buy
817,039
+3,367
+0.4% +$45K ﹤0.01% 2076
2021
Q4
$16.2M Buy
+813,672
New +$15.4M ﹤0.01% 1919

Other funds holding VTYX

Fidelity Investments's VTYX Position: Q1 2026 in Review

Fidelity Investments sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 11,422 shares — an estimated $103K sold.

Fidelity Investments first reported a position in VTYX in Q4 2021 and held it in 17 quarters. The position peaked at $301M in Q3 2023. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.

  • Fidelity Investments reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
  • Fidelity Investments sold 11,422 Ventyx Biosciences shares in Q1 2026, an estimated $103K.
  • Fidelity Investments first reported a position in Ventyx Biosciences in Q4 2021 and held it in 17 quarters.
  • Fidelity Investments's Ventyx Biosciences position peaked at $301M in Q3 2023.
  • 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.